The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The company plans to submit the IND application by the end of 2021
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
The goal for the project is the identification and optimization of anti-viral compounds.
Subscribe To Our Newsletter & Stay Updated
